Monte Rosa Therapeutics, Inc. (GLUE) entered into a supply agreement with Johnson & Johnson to support a Phase 2 study of its GSPT1‑directed molecular‑glue degrader, MRT‑2359, in combination with apalutamide (ERLEADA®) for patients with metastatic castration‑resistant prostate cancer (mCRPC) carrying androgen‑receptor mutations. The trial will enroll up to 25 patients and is slated to begin in the third quarter of 2026, with Monte Rosa conducting and sponsoring the study while Johnson & Johnson supplies apalutamide as part of the arrangement.
The decision to advance to Phase 2 was driven by compelling early data from the ongoing Phase 1/2 program. In the updated dataset presented at the 2026 ASCO Genitourinary Cancers Symposium, all five patients with AR mutations achieved a PSA response, including two PSA90 responses and three PSA50 responses. These results, reported in February 2026, underscored the drug’s activity in a population with limited therapeutic options.
"We are pleased to enter into this supply agreement with Johnson & Johnson to further explore the potential of MRT‑2359 in combination with next‑generation AR inhibitors such as apalutamide in patients with advanced prostate cancer," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "Based on the compelling clinical activity observed to date in heavily pretreated patients with AR mutations, we believe this combination approach holds significant promise," added Warmuth. Chief Medical Officer Filip Janku, M.D., Ph.D., added, "These data bolster the promising results we shared in December, continuing to reinforce MRT‑2359's potential in mCRPC patients with AR mutations, a population with limited therapeutic options."
The partnership expands Monte Rosa’s clinical portfolio and leverages Johnson & Johnson’s established drug, ERLEADA®, to potentially accelerate development of MRT‑2359. It also exemplifies Monte Rosa’s strategy of forming supply and collaboration agreements to advance its molecular‑glue platform while sharing development risk with large pharmaceutical partners. The agreement positions the program for advancement into registrational studies, with Monte Rosa planning to initiate the Phase 2 study this year to confirm MRT‑2359’s clinical activity.
The supply agreement represents a significant milestone for Monte Rosa, validating its MGD technology and providing a pathway to bring a novel therapy to patients with a high unmet need. By partnering with a major industry player, Monte Rosa gains access to a proven AR inhibitor and the infrastructure to support a rigorous clinical trial, enhancing the likelihood of regulatory success and future commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.